FDA Grants Priority Review to Tazemetostat for Relapsed/Refractory Follicular Lymphoma

The submission was primarily based on updated phase II efficacy and safety data for tazemetostat for patients with relapsed or refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy.

Source: CancerNetwork - February 14, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news